📊 BNGO Key Takeaways
Is Bionano Genomics, Inc. (BNGO) a Good Investment?
Bionano Genomics faces fundamental deterioration with declining revenue (-7.4% YoY) alongside severe unprofitability (-124.2% net margin) and significant cash burn (-$6.1M FCF). With only $3.4M in cash and negative operating cash flow of -$5.7M annually, the company has approximately 7 months of runway at current burn rates, creating existential risk despite zero debt.
Bionano Genomics shows weak fundamentals: revenue is declining, operating losses remain larger than revenue, and free cash flow is deeply negative. The balance sheet benefits from no long-term debt and acceptable near-term liquidity, but the very low cash balance relative to ongoing cash burn raises significant financing and going-concern risk unless operating performance improves materially.
Bionano Genomics, Inc. Key Strengths (BNGO)
- No long-term debt provides financial flexibility
- Current ratio of 1.84x indicates adequate near-term liquidity position
- Loss magnitude improving year-over-year (net income +76.4% improvement from negative base)
- No long-term debt, which reduces balance sheet leverage risk
- Current and quick ratios indicate near-term liabilities are still covered
- Negative EPS improved year over year, suggesting some cost or share-count-related improvement
BNGO Stock Risks: Bionano Genomics, Inc. Investment Risks
- Revenue declining 7.4% YoY while operating at massive loss—suggests inability to achieve scale or market traction
- Negative free cash flow of -$6.1M with only $3.4M cash available creates critical runway risk (approximately 7 months at current burn)
- Operating margin of -118% on $6.7M revenue indicates unsustainable unit economics and severe cost structure misalignment
- Capital expenditure continues ($344K) despite negative cash generation, draining limited cash reserves
- Revenue declined 14.8% year over year, indicating weak growth quality and limited commercial traction
- Operating margin of -120.7% and net margin of -89.8% show the business model is far from profitable
- Cash of $3.06M versus negative operating cash flow of $12.17M implies substantial liquidity pressure and likely need for external capital
Key Metrics to Watch
- Revenue growth inflection—currently declining; must stabilize and grow to extend runway
- Operating cash flow path to breakeven
- Cash burn rate and remaining cash runway
- Quarterly revenue growth and evidence of sustained commercial adoption
- Cash burn runway, especially operating cash flow and ending cash balance
Bionano Genomics, Inc. (BNGO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Bionano Genomics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BNGO Profit Margin, ROE & Profitability Analysis
BNGO vs Industrial Sector: How Bionano Genomics, Inc. Compares
How Bionano Genomics, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bionano Genomics, Inc. Stock Overvalued? BNGO Valuation Analysis 2026
Based on fundamental analysis, Bionano Genomics, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bionano Genomics, Inc. Balance Sheet: BNGO Debt, Cash & Liquidity
BNGO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bionano Genomics, Inc.'s revenue has grown significantly by 71% over the 5-year period, indicating strong business expansion. The most recent EPS of $-88.13 indicates the company is currently unprofitable.
BNGO Revenue Growth, EPS Growth & YoY Performance
BNGO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.5M | -$3.1M | $-0.76 |
| Q3 2025 | $6.1M | -$3.1M | $-1.59 |
| Q2 2025 | $6.7M | -$3.1M | $-1.99 |
| Q1 2025 | $6.5M | -$3.1M | $-1.15 |
| Q3 2024 | $6.1M | -$16.2M | $-0.52 |
| Q2 2024 | $7.8M | -$16.2M | $-0.24 |
| Q1 2024 | $7.4M | -$31.4M | $-0.60 |
| Q3 2023 | $7.2M | -$30.0M | $-1.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bionano Genomics, Inc. Dividends, Buybacks & Capital Allocation
BNGO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bionano Genomics, Inc. (CIK: 0001411690)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BNGO
What is the AI rating for BNGO?
Bionano Genomics, Inc. (BNGO) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BNGO's key strengths?
Claude: No long-term debt provides financial flexibility. Current ratio of 1.84x indicates adequate near-term liquidity position. ChatGPT: No long-term debt, which reduces balance sheet leverage risk. Current and quick ratios indicate near-term liabilities are still covered.
What are the risks of investing in BNGO?
Claude: Revenue declining 7.4% YoY while operating at massive loss—suggests inability to achieve scale or market traction. Negative free cash flow of -$6.1M with only $3.4M cash available creates critical runway risk (approximately 7 months at current burn). ChatGPT: Revenue declined 14.8% year over year, indicating weak growth quality and limited commercial traction. Operating margin of -120.7% and net margin of -89.8% show the business model is far from profitable.
What is BNGO's revenue and growth?
Bionano Genomics, Inc. reported revenue of $6.7M.
Does BNGO pay dividends?
Bionano Genomics, Inc. does not currently pay dividends.
Where can I find BNGO SEC filings?
Official SEC filings for Bionano Genomics, Inc. (CIK: 0001411690) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BNGO's EPS?
Bionano Genomics, Inc. has a diluted EPS of $-0.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BNGO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Bionano Genomics, Inc. has a D grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BNGO stock overvalued or undervalued?
Valuation metrics for BNGO: ROE of -22.2% (sector avg: 15%), net margin of -124.2% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is BNGO's AI grade for 2026?
Our dual AI analysis gives Bionano Genomics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BNGO's free cash flow?
Bionano Genomics, Inc.'s operating cash flow is $-5.7M, with capital expenditures of $344.0K. FCF margin is -90.6%.
How does BNGO compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -124.2% (avg: 10%), ROE -22.2% (avg: 15%), current ratio 1.84 (avg: 1.8).